Targeted treatments for chronic rhinosinusitis: future of personalized care

Chronic rhinosinusitis (CRS) is a complex inflammatory condition affecting the paranasal sinuses and upper airway, with significant variability in clinical presentation and treatment outcomes. Recent advancements in the understanding of CRS phenotypes and endotypes are driving the development of targeted therapeutics, offering a more personalized approach to care. Traditional treatment methods, including antibiotics, corticosteroids, and surgery, often fail to address the underlying inflammatory mechanisms, resulting in high recurrence rates. However, with the emergence of biologics and molecular diagnostics, clinicians now have the tools to tailor treatments based on the patient's specific inflammatory profile.

CRS has been classically differentiated by phenotypic characteristics, such as the presence or absence of nasal polyps (CRSwNP or CRSsNP). However, research now highlights the importance of endotypes, which classify CRS based on distinct immunological pathways, such as Type 1, Type 2, and Type 3 inflammation. These endotypes better predict treatment responses and guide the use of new therapies, particularly biologics targeting Type 2 inflammation, such as dupilumab and mepolizumab. Studies show that patients with Type 2-driven CRSwNP are more likely to benefit from biologics, which reduce polyp size and improve symptoms like nasal obstruction and loss of smell.

While biologic therapies represent a significant leap forward, challenges remain in identifying the right patients for these treatments, particularly given the cost and long-term nature of therapy. Ongoing research aims to refine the classification of CRS endotypes and improve the effectiveness of personalized treatment strategies, ultimately improving patient outcomes and reducing the need for surgical intervention.